These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 16118228)

  • 21. Different response to rituximab in tumor necrosis factor blocker-naive patients with active ankylosing spondylitis and in patients in whom tumor necrosis factor blockers have failed: a twenty-four-week clinical trial.
    Song IH; Heldmann F; Rudwaleit M; Listing J; Appel H; Braun J; Sieper J
    Arthritis Rheum; 2010 May; 62(5):1290-7. PubMed ID: 20461780
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Relationship between serum trough infliximab levels, pretreatment C reactive protein levels, and clinical response to infliximab treatment in patients with rheumatoid arthritis.
    Wolbink GJ; Voskuyl AE; Lems WF; de Groot E; Nurmohamed MT; Tak PP; Dijkmans BA; Aarden L
    Ann Rheum Dis; 2005 May; 64(5):704-7. PubMed ID: 15485995
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Flexibilization of infliximab dose interval in the treatment of ankylosing spondylitis].
    Vinagre F; Santos MJ; Silva JC
    Acta Reumatol Port; 2007; 32(3):271-3. PubMed ID: 17940497
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inflammatory biomarkers, disease activity and spinal disease measures in patients with ankylosing spondylitis after treatment with infliximab.
    Visvanathan S; Wagner C; Marini JC; Baker D; Gathany T; Han J; van der Heijde D; Braun J
    Ann Rheum Dis; 2008 Apr; 67(4):511-7. PubMed ID: 17644552
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A six-month randomized, controlled, double-blind, dose-response comparison of intravenous pamidronate (60 mg versus 10 mg) in the treatment of nonsteroidal antiinflammatory drug-refractory ankylosing spondylitis.
    Maksymowych WP; Jhangri GS; Fitzgerald AA; LeClercq S; Chiu P; Yan A; Skeith KJ; Aaron SL; Homik J; Davis P; Sholter D; Russell AS
    Arthritis Rheum; 2002 Mar; 46(3):766-73. PubMed ID: 11920413
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sustained effect after lowering high-dose infliximab in patients with rheumatoid arthritis: a prospective dose titration study.
    van den Bemt BJ; den Broeder AA; Snijders GF; Hekster YA; van Riel PL; Benraad B; Wolbink GJ; van den Hoogen FH
    Ann Rheum Dis; 2008 Dec; 67(12):1697-701. PubMed ID: 18245109
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prospective assessment of body weight, body composition, and bone density changes in patients with spondyloarthropathy receiving anti-tumor necrosis factor-alpha treatment.
    Briot K; Gossec L; Kolta S; Dougados M; Roux C
    J Rheumatol; 2008 May; 35(5):855-61. PubMed ID: 18381782
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab.
    Baraliakos X; Listing J; Brandt J; Zink A; Alten R; Burmester G; Gromnica-Ihle E; Kellner H; Schneider M; Sörensen H; Zeidler H; Rudwaleit M; Sieper J; Braun J
    Arthritis Res Ther; 2005; 7(3):R439-44. PubMed ID: 15899030
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Predictors of treatment response and drug continuation in 842 patients with ankylosing spondylitis treated with anti-tumour necrosis factor: results from 8 years' surveillance in the Danish nationwide DANBIO registry.
    Glintborg B; Ostergaard M; Krogh NS; Dreyer L; Kristensen HL; Hetland ML
    Ann Rheum Dis; 2010 Nov; 69(11):2002-8. PubMed ID: 20511613
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Infliximab in severe active ankylosing spondylitis with spinal ankylosis.
    Cheung PP; Tymms KE; Wilson BJ; Shadbolt B; Brook AS; Dorai Raj AK; Khoo KB
    Intern Med J; 2008 Jun; 38(6):396-401. PubMed ID: 18336538
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Persistent reduction of spinal inflammation as assessed by magnetic resonance imaging in patients with ankylosing spondylitis after 2 yrs of treatment with the anti-tumour necrosis factor agent infliximab.
    Sieper J; Baraliakos X; Listing J; Brandt J; Haibel H; Rudwaleit M; Braun J
    Rheumatology (Oxford); 2005 Dec; 44(12):1525-30. PubMed ID: 16091396
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Thalidomide for severe refractory ankylosing spondylitis: a 6-month open-label trial.
    Wei JC; Chan TW; Lin HS; Huang F; Chou CT
    J Rheumatol; 2003 Dec; 30(12):2627-31. PubMed ID: 14719205
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Anti-TNF-alpha treatment--an effective complement in spondyloarthropathy].
    Mandl T; Jacobsson L
    Lakartidningen; 2002 Dec; 99(51-52):5189-93. PubMed ID: 12572316
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Characteristics and treatment responses of patients satisfying the BSR guidelines for anti-TNF in ankylosing spondylitis.
    Gadsby K; Deighton C
    Rheumatology (Oxford); 2007 Mar; 46(3):439-41. PubMed ID: 17255137
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of infliximab in patients with ankylosing spondylitis over a two-year period.
    Braun J; Deodhar A; Dijkmans B; Geusens P; Sieper J; Williamson P; Xu W; Visvanathan S; Baker D; Goldstein N; van der Heijde D;
    Arthritis Rheum; 2008 Sep; 59(9):1270-8. PubMed ID: 18759257
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Clinical study of etanercept for treating ankylosing spondylitis].
    Liang LQ; Zhan ZP; Ye YJ; Fu D; Xu HS; Yang XY
    Nan Fang Yi Ke Da Xue Xue Bao; 2008 Aug; 28(8):1349-51. PubMed ID: 18753057
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MRI in predicting a major clinical response to anti-tumour necrosis factor treatment in ankylosing spondylitis.
    Rudwaleit M; Schwarzlose S; Hilgert ES; Listing J; Braun J; Sieper J
    Ann Rheum Dis; 2008 Sep; 67(9):1276-81. PubMed ID: 18006539
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of refractory inflammatory monoarthritis in ankylosing spondylitis by intraarticular injection of infliximab.
    Schatteman L; Gyselbrecht L; De Clercq L; Mielants H
    J Rheumatol; 2006 Jan; 33(1):82-5. PubMed ID: 16292792
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Improvement in hemoglobin levels in patients with ankylosing spondylitis treated with infliximab.
    Braun J; van der Heijde D; Doyle MK; Han C; Deodhar A; Inman R; de Vlam K; Burmester GR; Van den Bosch F; Xu S; Visvanathan S; Rahman MU
    Arthritis Rheum; 2009 Aug; 61(8):1032-6. PubMed ID: 19644896
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Infliximab treatment in patients with rheumatoid arthritis and spondyloarthropathies in clinical practice: adverse events and other reasons for discontinuation of treatment.
    Levälampi T; Korpela M; Vuolteenaho K; Moilanen E
    Scand J Rheumatol; 2008; 37(1):6-12. PubMed ID: 18189188
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.